Expression and clinical significance of glucose transporter 1, vascular endothelial growth factor C, and nuclear faetor-κB in invasive ductal carcinoma of the breast
Ge Jie1, Wang Ying2, Shen Tiexiao1, Wang Minghai1, Wang Rongyin1
1Department of Minimally Invasive Surgery, the Third People's Hospital of Bengbu, Bengbu 233000, China; 2School of Pharmacy, Bengbu Medical College, Bengbu 233000, China
Abstract:Objective To observe the expression and clinical significance of glucose transporter 1(GLUT-1), vascular endothelial growth factor C(VEGF-C), nuclear faetor-κB(NF-κB)in invasive ductal carcinoma of the breast.Methods The expression of GLUT-1, VEGF-C, and NF-κB in 117 cases of invasive ductal carcinoma and 51 cases of pericarcinous tissues collected from January 2011 to November 2014 was detected by immunohistochemistry. The patients were aged 20-79 years. The relationship between the expression of GLUT-1, VEGF-C, and NF-κB and the clinicopathological characteristics and survival times of the patients was then analyzed.Results Differences in GLUT-1, NF-κB, and VEGF-C expression in normal tissues, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and breast tissue with lymph node metastasis were statistically significant (χ2=45.785, 48.433, 48.236, all P values<0.01). The positive expression rates of GLUT-1, NF-κB, and VEGF-C were correlated with tumor size, lymphatic infiltration, TNM stage, and pathological grade (all P values<0.05). Of the 117 patients with invasive ductal carcinoma, 7 were lost to follow up and 32 passed away. Among 110 patients with infiltrating ductal carcinoma of the breast, the 5-year survival rate of patients with positive GLUT-1 expression (21.82%) was notably lower than that of patients with negative expression (77.09%); the difference observed was statistically significant (χ2=10.854,P<0.01). No significant difference in 5-year survival rate between patients with positive and negative NF-κB and VEGF-C expression was observed (χ2=0.843, 0.852, all P values>0.05).Conclusions Increased expression of GLUT-1, VEGF-C, and NF-κB may be involved in the invasion and progression of infiltrating ductal carcinoma of the breast. Moreover, GLUT-1 is a high-risk factor affecting the prognosis of patients.
葛杰, 王颖, 沈铁骁, 王名海, 王荣寅. 葡萄糖转运蛋白1、人类血管内皮生长因子C、核因子κB在乳腺浸润性导管癌组织中的表达及其对患者预后的影响[J]. 中华解剖与临床杂志, 2020, 25(5): 537-541.
Ge Jie, Wang Ying, Shen Tiexiao, Wang Minghai, Wang Rongyin. Expression and clinical significance of glucose transporter 1, vascular endothelial growth factor C, and nuclear faetor-κB in invasive ductal carcinoma of the breast. Chinese Journal of Anatomy and Clinics, 2020, 25(5): 537-541.
Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. Breast cancer in the 21st century: from early detection to new therapies[J]. Radiologia, 2017, 59(5): 368-379. DOI:10.1016/j.rx.2017.06.003.
[2]
Schwartz L, Supuran CT, Alfarouk KO. The warburg effect and the hallmarks of cancer[J]. Anticancer Agents Med Chem, 2017, 17(2): 164-170. DOI:10.2174/1871520616666161031143301.
[3]
Pan Y, Zheng Q, Ni W, et al. Breaking glucose transporter 1/pyruvate kinase M2 glycolytic loop is required for cantharidin inhibition of metastasis in highly metastatic breast cancer[J]. Front Pharmacol, 2019, 10: 590. DOI:10.3389/fphar.2019.00590.
[4]
Tsutsui S, Inoue H, Yasuda K, et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density[J]. Breast Cancer Res Treat, 2006, 98(3): 261-266. DOI:10.1007/s10549-005-9157-9.
[5]
Zhao H, Sun J, Shao J, et al. Glucose transporter 1 promotes the malignant phenotype of non-small cell lung cancer through integrin β1/Src/FAK signaling[J]. J Cancer, 2019, 10(20): 4989-4997. DOI:10.7150/jca.30772.
[6]
Sun H, Miao C, Liu W, et al. TGF-β1/TβRII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages[J]. Biochem Biophys Res Commun, 2018, 497(2): 583-590. DOI:10.1016/j.bbrc.2018.02.104.
[7]
Long L, Pang XX, Lei F, et al. SLC52A3 expression is activated by NF-κB p65/Rel-B and serves as a prognostic biomarker in esophageal cancer[J]. Cell Mol Life Sci, 2018, 75(14): 2643-2661. DOI:10.1007/s00018-018-2757-4.
[8]
姜洋, 金晓明, 屠康. 平均阳性染色面积百分比法分析免疫组化结果初探[J]. 生物医学工程学杂志, 2007, (03): 650-653. DOI:10.3969/j.issn.1671-4695.2018.03.015.Jiang Y, Jin XM, Tu K, et al. A primary study using the method of average positive stained area percentage to measure the immunohistochemistry results[J]. Journal of Biomedical Engineering, 2007, 24(3): 650-653. DOI:10.3321/j.issn:1001-5515.2007.03.039.
[9]
Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options[J]. J Clin Oncol, 2015, 33(23): 2563-2577. DOI:10.1200/JCO.2015.61.6706.
[10]
Wahdan-Alaswad RS, Edgerton SM, Salem HS, et al. Metformin targets glucose metabolism in triple negative breast cancer[J]. J Oncol Transl Res, 2018, 4(1) DOI:10.4172/2476-2261.1000129.
[11]
Li Z, Gong X, Zhang W, et al. Inhibition of miRNA-34a promotes triple negative cancer cell proliferation by promoting glucose uptake[J]. Exp Ther Med, 2019, 18(5): 3936-3942. DOI:10.3892/etm.2019.8017.
[12]
Ancey PB, Contat C, Meylan E. Glucose transporters in cancer—from tumor cells to the tumor microenvironment[J]. FEBS J, 2018, 285(16): 2926-2943. DOI:10.1111/febs.14577.
[13]
Kurahara H, Maemura K, Mataki Y, et al. Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2018, 25(5): 1432-1439. DOI:10.1245/s10434-018-6357-1.
[14]
Schlüter A, Weller P, Kanaan O, et al. CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma[J]. BMC Cancer, 2018, 18(1): 272. DOI:10.1186/s12885-018-4180-5.
[15]
Katz H, Jafri H, Saad R, et al. Colonic obstruction from an unusual cause: a rare case of metastatic invasive ductal carcinoma to the colon[J]. Cureus, 2018, 10(5): e2588. DOI:10.7759/cureus.2588.
[16]
Wolff M, Kosyna FK, Dunst J, et al. Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells[J]. Arch Biochem Biophys, 2017, 613: 23-30. DOI:10.1016/j.abb.2016.11.002.
[17]
Halle MK, Ojesina AI, Engerud H, et al. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study[J]. Am J Obstet Gynecol, 2017, 217(4): 432.e1-432.e17. DOI:10.1016/j.ajog.2017.05.068.
[18]
王丽, 孙爱东, 袁昕, 等. 喉癌术后辅助放疗患者癌组织缺氧诱导因子-1α、葡萄糖转运蛋白-1表达及其与预后的相关性分析[J]. 临床和实验医学杂志, 2018, 17(03): 273-277. DOI:10.3969/j.issn.1671-4695.2018.03.015.Wang L,Sun AD,Yuan X,ea al.Expression of hypoxia inducible factor-1α and glucose transporter-1 in laryngeal carcinoma after adjuvant radiotherapy for larynge-al carcinoma and its correlation with prognosis[J]. Journal of Clinical and Experimental Medicine, 2018, 17(3): 273-277. DOI:10.3969/j.issn.1671-4695.2018.03.015.
[19]
Zhang B, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: a meta-analysis[J]. Gene, 2019, 689: 76-83. DOI:10.1016/j.gene.2018.12.006.